I. MODIFIED AGREEMENTS |
||||
Chrysalin BioTechnology Inc.* | OrthoLogic Corp. (OLGC) | Expansion of 1/99 agreement covering fracture healing indications for Chrysalin (synthetic 23-amino-acid peptide) in the U.S. (7/00) | $2 | OrthoLogic will pay Chrysalin a one-time fee of $2M, plus milestones and possible royalties to expand license to include all orthopedic indications and extend agreement worldwide |
Emisphere Technologies Inc. (EMIS) | Eli Lilly and Co. (NYSE:LLY) | Expansion of 2/97 development and research collaboration for oral formulations of Forteo and Humatrop utilizing Emisphere's proprietary drug delivery technology | $2 | The new agreement provides for supplemental research and development funding; Emisphere will immediately receive a $2M milestone payment under the terms in the previous agreement (6/00) |
Exelixis Inc. (EXEL) | Bristol-Myers Squibb Co. (NYSE:BMY) | Expansion of 9/99 technology access and research agreement under which Exelixis identifies the mechanism of action for pharmaceutical compounds received from Bristol-Myers | ND | Bristol-Myers will double its committed research funding for the remainder of the agreement (6/00) |
Icos Corp. (ICOS) | Abbott Laboratories (NYSE:ABT) | Change in 1995 agreement covering LFA-1 antagonists for inflammation | ND | Icos acquired marketing rights for all compounds in all indications worldwide; Abbott will receive royalties on any marketed products (6/00) |
Incyte Genomics Inc. (INCY) | Aventis Research & Technologies GmbH & Co. KG (NYSE:AVE) | Expansion of collaboration; Incyte has had agreements with Rhone Poulenc SA and Hoechst AG (since merged to form Aventis) | ND | Incyte expanded its agreement with Aventis to include access to to Incyte's custom SNP program and will focus on identifying individual single nucleotide polymorphisms that affect drug matabolism (6/00) |
Incyte Genomics Inc. (INCY) | Eli Lilly and Co. (NYSE:LLY) | Expansion of 12/96 database subscription agreement; companies will collaborate on the development of therapeutic proteins | ND | Eli Lilly will obtain options to license multiple therapeutic protein patents from Incyte (6/00) |
Karo Bio AB-(Sweden; SSE:KARO) | Bristol-Myers Squibb Co. (NYSE:BMY) | Extension of 10/97 development agreement focused on the development of substances acting selectively on thyroid hormone receptor as a way to regulate dysmetabolic syndromes while sparing cardiovascular side effects | ND | The two companies have created first-generation drugs and will now focus on developing second-generation lead compounds (7/00) |
NaPro Bio Therapeutics Inc. (NPRO) | F.H. Faulding & Co. Ltd.* (Australia) | Expansion of 1/95 development and marketing collaboration for NaPro's paclitaxel | ND | Companies expanded agreement to provide Faulding exclusive rights in all of Central America, South America, Mexico, South Africa and certain additional territories in Southeast Asia and the Middle East (6/00) |
Oxford BioMedica (UK; LSE:OXB) | Aventis Pharmaceuticals Inc. (NYSE:AVE) | Extension of 12/98 collaboration that gave Aventis rights to use BioMedica's Hypoxia Response Element (HRE) in gene therapy for cardiovascular disease | ND | Under the new agreement, Aventis will have access to BioMedica's proprietary LentiVector gene delivery vectors in cardiovascular gene therapy product research and development programs (6/00) |
OSI Pharmaceuticals Inc. (OSIP) | Pfizer Inc. (NYSE:PFE) | New licensing agreement for Phase II anticancer compound, CP-358,774 (OSI-774), that emerged from collaboration begun | ND | OSI gains all development and marketing rights to CP-358,774 (OSI-774); OSI will receive royalty-free license to all rights for the further development and commercialization of the product; Pfizer had to license the compound to OSI because Warner-Lambert Co., which Pfizer acquired, was developing a similar product (7/00) |
SkyePharma plc (UK; SKYE) | Pfizer Inc. (NYSE:PFE) | Addition to development agreement of 3/00 with Pfizer; SkyePharma is using its proprietary DepoFoam sustained-release injection technology to formulate a Pfizer compound | ND | ND (5/00) |
Xoma Ltd. (XOMA) | Allergan (NYSE:AGN) | Expansion of 6/99 development collaboration for ophthalmic anti-infective product that combines rBPI (recombinant bactericidal permeability-increasing protein) with antibiotics to treat bacterial eye infections | ND | The amended agreement provides for additional milestone payments; Allergan will continue to pay all future development costs and Xoma will be entitled to royalties on net sales worldwide on all Allergan anti-infective products that incorporate rBPI; a Xoma affiliate will manufacture rBPI for Allergan (5/00) |
II. TERMINATED AGREEMENTS |
||||
Alkermes Inc. (ALKS) | Johnson & Johnson (NYSE:JNJ) | J&J terminated 1/98 collaboration to develop sustained-release formulation of erythro-poietin using Alkermes' ProLease technology | ND | Original agreement was worth more than $30M; no reason was given for the project's demise (6/00) |
NOTES |
||||
# The information in the chart does not cover agreements between biotech companies or agricultural agreements. |
||||
* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the NASDAQ market. |
||||
ND = Not disclosed, reported and/or available |
||||
AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over The Counter Bulletin Board. |
||||